Health Care • Biotechnology: Pharmaceutical Preparations
$21.31 ▲ +0.19
(+0.90%)
MKT CAP: $1.54B • VOL: 626.9K
52W L $18 52W H $25
ROARABLE / RQD
B • 75/100
PIOTROSKI
6 / 9
INVA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $411.3M | $358.7M | $310.5M |
| YoY Revenue Growth % | +14.7% | +15.5% | — |
| Gross Profit | $307.7M | $296.2M | — |
| Gross Margin % | 74.8% | 82.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $163.7M | $166.9M | $113.9M |
| Operating Margin % | 39.8% | 46.5% | 36.7% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | $164.6M | $167.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $196.9M | $188.7M | $141.1M |
| Capital Expenditures (CapEx) | $1.1M | $270.0K | — |
| Free Cash Flow (FCF) | $195.8M | $188.4M | $141.1M |
| FCF Margin % | 47.6% | 52.5% | 45.4% |
| Return on Invested Capital (ROIC %) | 14.7% | 20.5% | — |
| Cash & Short-Term Equivalents | $550.9M | $305.0M | — |
| Total Debt (Short + Long Term) | $257.7M | $256.3M | — |
| Total Stockholders' Equity | $1.17B | $691.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INVA.